Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This target is a long non-coding RNA (lncRNA) transcribed antisense to the fibroblast growth factor receptor 1 (FGFR1) gene. According to gene databases and search content, there is no established evidence that this lncRNA encodes a protein or has a clear, validated biological or therapeutic function. It is classified as a non-coding RNA and not as a conventional receptor, enzyme, or therapeutic target. There is currently insufficient information to suggest that drugs interact directly with this lncRNA, and its role in disease or as a biomarker is undefined[3].\n\nKey point: This gene should not be considered a therapeutic target in the classical sense. If the intent was FGFR1 (Fibroblast growth factor receptor 1), that is a distinct and well-characterized receptor tyrosine kinase with therapeutic relevance[7]. The current entry, however, does not map to an actionable drug target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to fibroblast growth factor receptor 1 (ENSG00000305763).